RE-BVS – Piemonte Repository

Sfoglia per AUTORE
LORUSSO V
Collezione AOU San Luigi di Orbassano

Items : 5

Is imaging accurate enough to detect index lesion in prostate cancer? Analysis of the performance of MRI and other imaging modalities. in Minerva urology and nephrology / Minerva Urol Nephrol. 2024 Feb;76(1):22-30. doi: 10.23736/S2724-6051.23.05285-0. Epub 2023 Oct 10.

2024
AOU San Luigi di Orbassano

Pignot G; Gregori A; Fiori C; Granata AM; Branger N; Palmisano F; Talso M; Lorusso V; Walz J;

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). in Tumori / Tumori. 2023 Jun;109(3):324-334. doi: 10.1177/03008916221099558. Epub 2022 Jun 8.

2023
ASL Torino 4
AOU San Luigi di Orbassano

Iannelli Patient E; D'Acunti A; Nicelli A; De Persis D; Bassi M; Ferrari A; Bagnalasta M; Capelletto E; Adamo V; Cognetti F; Passalacqua R; Tortora G; Maruzzo M; Cogoni AA; Lorusso V; Calabrò F; Falzetta A; Cinieri S; Del Mastro L; Procopio G; Porta C; Novello S; Sparavigna L; Iezzi E; Diodati F; Ng D; Mitchell SA; Perrone F; Riva S; et alii...

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. in Clinical lung cancer / Clin Lung Cancer. 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.cllc.2014.04.004. Epub 2014 May 14.

2014
AOU San Luigi di Orbassano

de Marinis F; Ardizzoni A; Fontanini G; Grossi F; Cappuzzo F; Novello S; Santo A; Lorusso V; Cortinovis D; Iurlaro M; Galetta D; Gridelli C;

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. in British journal of cancer / Br J Cancer. 2005 Feb 28;92(4):634-8. doi: 10.1038/sj.bjc.6602335.

2005
AOU San Luigi di Orbassano

Berruti A; Bitossi R; Gorzegno G; Bottini A; Generali D; Milani M; Katsaros D; Rigault de la Longrais IA; Bellino R; Donadio M; Ardine M; Bertetto O; Danese S; Sarobba MG; Farris A; Lorusso V; Dogliotti L;

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012.

2002
AOU San Luigi di Orbassano

Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;